BRCA1-mimetic compound NSC35446.HCl inhibits IKKB expression by reducing estrogen receptor-α occupancy in the IKKB promoter and inhibits NF-κB activity in antiestrogen-resistant human breast cancer cells

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2017-08-14

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1007/s10549-017-4442-yPMID 28808806PMCID PMC5681404
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Structural and Molecular Mechanisms of Cytokine-Mediated Endocrine Resistance in Human Breast Cancer Cells.

  2017cited by this paper
• Surface Plasmon Resonance Study of Cooperative Interactions of Estrogen Receptor α and Specificity Protein 1 with Composite DNA Elements.

  2016cited by this paper
• A new class of small molecule estrogen receptor-alpha antagonists that overcome anti-estrogen resistance

  2015cited by this paper
• Small-molecule "BRCA1-mimetics" are antagonists of estrogen receptor-α.

  2014cited by this paper
• Links between genome integrity and BRCA1 tumor suppression.

  2012cited by this paper
• Expanding the paradigm for estrogen receptor binding and transcriptional activation.

  2011cited by this paper
• BRCA1 and BRCA2: different roles in a common pathway of genome protection

  2011cited by this paper
• Location analysis for the estrogen receptor-α reveals binding to diverse ERE sequences and widespread binding within repetitive DNA elements

  2010influential reference
• 17β-Estradiol enhances α5 integrin subunit gene expression through ERα–Sp1 interaction and reduces cell motility and invasion of ERα-positive breast cancer cells

  2010cited by this paper
• BCL2 and CASP8 regulation by NF‐κB differentially affect mitochondrial function and cell fate in antiestrogen‐sensitive and ‐resistant breast cancer cells

  2010influential reference
• BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha.

  2010cited by this paper
• IFNγ Restores Breast Cancer Sensitivity to Fulvestrant by Regulating STAT1, IFN Regulatory Factor 1, NF-κB, BCL2 Family Members, and Signaling to Caspase-Dependent Apoptosis

  2010cited by this paper
• Estrogen regulated expression of the p21Waf1/Cip1 gene in estrogen receptor positive human breast cancer cells

  2010cited by this paper
• Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells.

  2009cited by this paper
• Surface plasmon resonance study of cooperative interactions of estrogen receptor alpha and transcriptional factor Sp1 with composite DNA elements.

  2009cited by this paper
• Regulation of programmed cell death by NF-kappaB and its role in tumorigenesis and therapy.

  2008cited by this paper
• Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERα-negative and ERα-positive mammary preneoplasia and cancer

  2008cited by this paper
• Decreased BRCA1 Confers Tamoxifen Resistance in Breast Cancer Cells by Altering Estrogen Receptor-Coregulator Interactions

  2008cited by this paper
• CBP Is a dosage-dependent regulator of nuclear factor-kappaB suppression by the estrogen receptor.

  2008cited by this paper
• Long-range activation of GREB1 by estrogen receptor via three distal consensus estrogen-responsive elements in breast cancer cells.

  2007influential reference
• The nuclear factor κB inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)–induced apoptosis in antiestrogen-resistant breast cancer cells

  2005cited by this paper
• The nuclear factor kappa B inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells.

  2005influential reference
• Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer

  2005cited by this paper
• Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis.

  2005cited by this paper
• Tissue transglutaminase-induced alterations in extracellular matrix inhibit tumor invasion

  2005cited by this paper
• Structural determinants of the BRCA1 : estrogen receptor interaction

  2005cited by this paper
• Identification of pathway-selective estrogen receptor ligands that inhibit NF-kappaB transcriptional activity.

  2005cited by this paper
• Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer.

  2005cited by this paper
• Regulation of the estrogen-inducible gene expression profile by the breast cancer susceptibility gene BRCA1.

  2005cited by this paper
• Estrogen, heat shock proteins, and NFkappaB in human vascular endothelium.

  2004cited by this paper
• Estrogen, Heat Shock Proteins, and NF&kgr;B in Human Vascular Endothelium

  2004cited by this paper
• Interferon Regulatory Factor-1 Mediates the Proapoptotic but Not Cell Cycle Arrest Effects of the Steroidal Antiestrogen ICI 182,780 (Faslodex, Fulvestrant)

  2004cited by this paper
• Action of “pure” antiestrogens in inhibiting estrogen receptor action

  2004cited by this paper
• Interplay between Estrogen Response Element Sequence and Ligands Controls in Vivo Binding of Estrogen Receptor to Regulated Genes*

  2004cited by this paper
• BRCA1 Augments Transcription by the NF-κB Transcription Factor by Binding to the Rel Domain of the p65/RelA Subunit*

  2003cited by this paper
• Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780).

  2002cited by this paper
• p300 Modulates the BRCA1 inhibition of estrogen receptor activity.

  2002cited by this paper
• Estrogen receptor inducibility of the human Na+/H+ exchanger regulatory factor/ezrin-radixin-moesin binding protein 50 (NHE-RF/EBP50) gene involving multiple half-estrogen response elements.

  2002cited by this paper
• Cellular and molecular pharmacology of antiestrogen action and resistance.

  2001cited by this paper
• Role of direct interaction in BRCA1 inhibition of estrogen receptor activity

  2001cited by this paper
• Estrogen receptor alpha interaction with estrogen response element half-sites from the rat prolactin gene.

  2000cited by this paper
• Mutations in the Estrogen Receptor Ligand Binding Domain Discriminate between Hormone-dependent Transactivation and Transrepression*

  2000cited by this paper
• Estrogen Receptor α Interaction with Estrogen Response Element Half-Sites from the Rat Prolactin Gene†

  2000cited by this paper
• Sp1 binding sites and an estrogen response element half-site are involved in regulation of the human progesterone receptor A promoter.

  2000cited by this paper
• BRCA1 inhibition of estrogen receptor signaling in transfected cells.

  1999cited by this paper
• MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.

  1997cited by this paper
• Interferon Regulatory Factor Element and Interferon Regulatory Factor 1 in the Induction of Major Histocompatibility Complex Class I Genes in Neural Cells

  1995cited by this paper
• A potent specific pure antiestrogen with clinical potential.

  1991cited by this paper
• T47DCO cells, genetically unstable and containing estrogen receptor mutations, are a model for the progression of breast cancers to hormone resistance.

  1990cited by this paper
• Cooperative binding of estrogen receptor to imperfect estrogen‐responsive DNA elements correlates with their synergistic hormone‐dependent enhancer activity.

  1989influential reference
• Cell‐specific activity of a GGTCA half‐palindromic oestrogen‐responsive element in the chicken ovalbumin gene promoter.

  1988cited by this paper
• Acceptor sites on chromatin for receptor bound by estrogen versus antiestrogen in antiestrogen-sensitive and -resistant MCF-7 cells.

  1986cited by this paper
• Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY 117018.

  1985cited by this paper

• Inhibition of NF-κB signaling unveils novel strategies to overcome drug resistance in cancers.

  2024cites this paper
• The role of estrogen receptors (ERs)-Notch pathway in thyroid toxicity induced by Di-2-ethylhexyl phthalate (DEHP) exposure: Population data and in vitro studies.

  2023cites this paper
• Long non-coding RNA MEG3 promotes tumor necrosis factor-alpha induced oxidative stress and apoptosis in interstitial cells of cajal via targeting the microRNA-21 /I-kappa-B-kinase beta axis

  2022cites this paper
• Update on the role of NFκB in promoting aggressive phenotypes of estrogen receptor (ER) positive breast cancer.

  2020cites this paper
• The novel circ_0028171/miR-218-5p/IKBKB axis promotes osteosarcoma cancer progression

  2020cites this paper
• Triptolidenol, isolated from Tripterygium wilfordii, disrupted NF-κB/COX-2 pathway by targeting ATP-binding sites of IKKβ in clear cell renal cell carcinoma.

  2020cites this paper
• Dual Modulators of p53 and Cyclin D in ER Alpha Signaling by Albumin Nanovectors Bearing Zinc Chaperones for ER Positive Breast Cancer Therapy.

  2020cites this paper
• Targeting the estrogen receptor alpha (ERα)-mediated circ-SMG1.72/miR-141-3p/Gelsolin signaling to better suppress the HCC cell invasion

  2020cites this paper
• Endocrinotherapy resistance of prostate and breast cancer: Importance of the NF‑κB pathway (Review).

  2020cites this paper
• ACT001 can prevent and reverse tamoxifen resistance in human breast cancer cell lines by inhibiting NF‐κB activation

  2018cites this paper